ACE inhibitors in cardiovascular disease. which patient? which drug? which dose?
Pellizzer, A.M.; Krum, H.
Australian Family Physician 25(7): 1067-1069; 1072-3; 1076-1077
1996
ISSN/ISBN: 0300-8495 PMID: 8768273 Document Number: 463604
The increasing role of angiotensin converting enzyme (ACE) inhibitor therapy in cardiovascular disease makes it important for the practising clinician to be aware of the specific benefits afforded by these agents. This article covers the use of ACE inhibitors in hypertension, chronic heart failure, post myocardial infarction, diabetic nephropathy and atherosclerosis, with specific reference to clinical trial data and proposed mechanisms of effect.
Document emailed within 1 workday
Related Documents
Colpaert, F.C.; Janssen, P.A. 1982: Factors regulating drug cue sensitivity: the effects of dose ratio and absolute dose level in the case of fentanyl dose-dose discrimination Archives Internationales de Pharmacodynamie et de Therapie 258(2): 283-299Becker, W. 2005: High-dose vitamins can be dangerous! no protection against gastrointestinal cancer or cardiovascular disease Lakartidningen 102(10): 728
De Caterina, R. 2003: Low-dose aspirin in the primary prevention of cardiovascular disease: how to balance the benefits and the risks Italian Heart Journal: Official Journal of the Italian Federation of Cardiology 4(4): 228-231
1992: ACE inhibitors and end-organ damage in cardiovascular disease: kidney and nervous system in hypertension. Proceedings of the Erasmus Medical Workshops Journal of Cardiovascular Pharmacology 19 Suppl. 6: S1-145
Bonnici, F.; Omar, M.A. 1991: Should ACE inhibitors be the drugs of choice in the treatment of hypertension in diabetes mellitus? ACE inhibitors have a more beneficial effect on biochemical parameters than low-dose thiazides South African Medical Journal 80(5): Suppl 6
Crismon, M.L. 1998: Pharmacokinetics and drug interactions of cholinesterase inhibitors administered in Alzheimer's disease PharmacoTherapy 18(2 Part 2): 47-54; Discussion: 79-82
2009: Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors Prescrire International 18(101): 108-110
Chuchottaworn, C.; Saipan, B.; Kittisup, C.; Cheewakul, K. 2012: Adverse drug reactions and outcome of short course anti-tuberculosis drugs between single daily dose and split drug dose (BID) in pulmonary tuberculosis Journal of the Medical Association of Thailand 95(Suppl 8): S1-S5
Nishikimi, T. 2010: Molecular target drug for hypertension and cardiovascular disease Nihon Rinsho. Japanese Journal of Clinical Medicine 68(10): 1911-1916
Baig, S.Z.; Coats, W.C.; Aggarwal, K.B.; Alpert, M.A. 2009: Assessing cardiovascular disease in the dialysis patient Advances in Peritoneal Dialysis. Conference on Peritoneal Dialysis 25: 147-154
Goicoechea, M.A. 2004: Cardiovascular disease in patients with 4 and 5 stage chronic kidney disease. Patient in chronic dialysis Nefrologia: Publicacion Oficial de la Sociedad Espanola Nefrologia 24 Suppl (6): 142-160; 187-235
García López, S. 2008: Inflammatory bowel disease. If a patient with Crohn's disease remains in remission for 4 years with azathioprine (or mercaptopurine), should the drug be withdrawn? Gastroenterologia y Hepatologia 31(10): 704-705
Lala, A.; Berger, J.S. 2011: Percutaneous coronary intervention for acute coronary syndromes: no difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarction or stroke compared with standard dose but increases risk of major bleeding Evidence-Based Medicine 16(3): 80-81
Richman, D.D.; Grimes, J.M.; Lagakos, S.W. 1990: Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus Journal of Acquired Immune Deficiency Syndromes 3(8): 743-746
Di Napoli, M.; McLaughlin, B. 2005: The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors Current Opinion in Investigational Drugs 6(7): 686-699
Pinel, B.; Cambon, C.; Thomine, J.M.; Cauvin, M.; Daragon, A.; Deshayes, P. 1984: Osteolysis, then fracture of the femur in a Paget's disease patient treated with high-dose disodium etidronate Revue du Rhumatisme et des Maladies Osteo-Articulaires 51(7-8): 417-418
Choi, J.-y.; Kwon, O.-K.; Choi, S.Y.; Park, Y.K.; Kim, S.S. 2011: Drug susceptibility of human immunodeficiency virus type 1-derived pseudoviruses from treatment-experienced patients to protease inhibitors and reverse transcriptase inhibitors, using a modified single-round assay Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology 50(1): 19-25
Schrager, S.; Dalby, J.; Hayon, R.; Fox, K. 2013: Cardiovascular disease in women: contraceptive issues and nonvalvular cardiovascular disease Fp Essentials 411: 28-33
Aghaeishahsavari, M.; Noroozianavval, M.; Veisi, P.; Parizad, R.; Samadikhah, J. 2006: Cardiovascular disease risk factors in patients with confirmed cardiovascular disease Saudi Medical Journal 27(9): 1358-1361
Stringer, J.S.A.; Sinkala, M.; Chapman, V.; Acosta, E.P.; Aldrovandi, G.M.; Mudenda, V.; Stout, J.P.; Goldenberg, R.L.; Kumwenda, R.; Vermund, S.H. 2003: Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine Aids 17(11): 1659-1665